Business Context and Reporting Period
Company: Illumina, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: Illumina is a leading developer of next-generation life science tools for genetic analysis, including sequencing, genotyping, and gene expression. The company operates in a single business segment. A significant corporate event occurred shortly after the reporting period: on January 26, 2007, Illumina completed the acquisition of Solexa, Inc. for approximately 13.1 million shares of common stock, expanding its capabilities into whole-genome resequencing.
Key Financial Metrics
| Metric (in thousands) | 2006 | 2005 |
|---|---|---|
| Total Revenue | $184,586 | $73,501 |
| Net Income (Loss) | $39,968 | $(20,874) |
| Diluted EPS | $0.82 | $(0.52) |
| Operating Cash Flow | $39,000 | $(9,008) |
| Cash & Short-term Investments | $130,804 | $50,822 |
| Working Capital | $159,950 | $57,992 |
| Long-term Debt | $0 | $54 |
| Accumulated Deficit | $(104,618) | $(144,586) |
Margins: Gross margin on product revenue was 67.1% in 2006, up from 65.5% in 2005. Gross margin on service and other revenue was 70.6% in 2006, down from 76.6% in 2005.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 151% to $184.6 million, driven primarily by a 170% increase in product revenue ($155.8 million). This growth was fueled by the launch of whole-genome genotyping products (HumanHap300 and HumanHap550 BeadChips) and a doubling of the installed base of BeadArray Readers.
- Profitability: The company achieved its first annual net income of $40.0 million, reversing a net loss of $20.9 million in 2005. Operating income improved from a loss of $21.4 million to a profit of $37.8 million.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 92% to $54.1 million, largely due to increased personnel costs, stock-based compensation ($8.9 million), and legal fees related to the Affymetrix litigation ($5.3 million). R&D expenses increased 20% to $33.4 million.
- Stock-Based Compensation: The adoption of SFAS No. 123R resulted in a $14.3 million non-cash stock-based compensation expense in 2006, compared to only $0.3 million in 2005.
Guidance, Outlook, Risks, and Unusual Items
- Outlook: Management expects R&D and SG&A expenses to increase in absolute dollars in 2007 to support the integration of Solexa and the launch of new products. The company anticipates continued revenue growth from new product launches and an expanding installed base.
- Subsequent Financing: In February 2007, the company issued $400 million in 0.625% Convertible Senior Notes due 2014. Net proceeds were approximately $390.3 million, with $202 million used to repurchase common stock.
- Key Risks:
- Litigation: Ongoing patent infringement litigation with Affymetrix, Inc. Trial was scheduled for March 2007. An adverse ruling could result in injunctions or significant damages.
- Acquisition Integration: Risks associated with integrating Solexa, including potential loss of key employees, diversion of management attention, and failure to realize anticipated synergies.
- Competition: Intense competition from companies like Affymetrix, Agilent, and Applied Biosystems could lead to price reductions or obsolescence of Illumina's technology.
- Manufacturing: Reliance on single vendors for key components (fiber optic bundles, BeadChip slides) creates supply chain risks.
- Unusual Items: In 2005, the company recorded a $15.8 million charge for acquired in-process research and development (IPR&D) related to the CyVera acquisition. No such charge was recorded in 2006.
Investor Verification Checklist
- Legal Proceedings: Monitor the outcome of the Affymetrix patent litigation trial scheduled for March 2007, as an adverse ruling could materially impact operations.
- Solexa Integration: Verify the successful integration of Solexa's sequencing technology and the commercial launch of the Illumina Genome Analyzer.
- Convertible Notes: Review the terms of the $400 million convertible notes issued in February 2007 and the associated hedge transactions for potential dilution impacts.
- Stock-Based Compensation: Assess the ongoing impact of SFAS No. 123R on future earnings, given the significant increase in non-cash compensation expenses in 2006.
- International Revenue: Confirm the stability of international sales, which accounted for 44% of total revenue in 2006, amidst potential currency fluctuations and geopolitical risks.